Peering into the future: Hepcidin testing

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages 976-978

  Goyal, Jatinder ^a   Mccleskey, Brandi ^a   Adamski, Jill ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FERROPORTIN; HEPCIDIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CHRONIC KIDNEY DISEASE; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; HUMAN; INTESTINE CELL; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; LIVER CELL; MASS SPECTROMETRY; PRIORITY JOURNAL;

EID: 84886252395     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23519     Document Type: Article

References (25)

1. Pantopoulos K, Porwal SK, Tartakoff A, et al. Mechanisms of mammalian iron homeostasis. Biochemistry 2012;51:5705-5724.
2. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
3. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 2010;55:726-741.
4. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.
5. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
6. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338:768-772.
7. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. II. Iron deficiency and iron overload. J Clin Pathol 2011;64:287-296.
8. Kemna EH, Tjalsma H, Podust VN, et al. Mass spectrometry-based hepcidin measurements in serum and urine: Analytical aspects and clinical implications. Clin Chem 2007;53:620-628.
9. Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 2009;94:1748-1752.
10. Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol 2012;87:977-983.
11. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-1579.
12. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.
13. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012;87:392-400.
14. Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013;88:97-101.
15. Nakanishi T, Kuragano T, Kaibe S, et al. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012.
16. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-1056.
17. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976-981.
18. Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: Associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009;39:883-890.
19. van der Putten K, Jie KE, van den Broek D, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010;12:943-950.
20. Ford BA, Eby CS, Scott MG, et al. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 2010;78:769-773.
21. van Bokhoven MA, van Deursen CT, Swinkels DW. Diagnosis and management of hereditary haemochromatosis. BMJ 2011;342:c7251.
22. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol 2009;4:489-515.
23. Sham RL, Phatak PD, Nemeth E, et al. Hereditary hemochromatosis due to resistance to hepcidin: High hepcidin concentrations in a family with C326S ferroportin mutation. Blood 2009;114:493-494.
24. Silvestri L, Pagani A, Nai A et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008;8:502-511.
25. Finberg KE, Heeney MM, Campagna DR et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008;40:569-571.